A comparative study of immunotherapy as second-line treatment and beyond in patients with advanced non-small-cell lung carcinoma.

Pub Date : 2021-03-11 eCollection Date: 2021-09-01 DOI:10.2217/lmt-2020-0027

Jerónimo Rafael Rodríguez-Cid, Sonia Carrasco-Cara Chards, Iván Romarico González-Espinoza, Vanessa García-Montes, Julio César Garibay-Díaz, Osvaldo Hernández-Flores, Rodrigo Riera-Sala, Anna Gozalishvili-Boncheva, Jorge Arturo Alatorre-Alexander, Luis Manuel Martínez-Barrera, Carla Paola Sánchez-Ríos, Adriana Martinez-Camacho, José Fabián Martínez-Herrera, Jordi Guzmán-Casta, Rodrigo Rafael Flores-Mariñelarena, Julián Diaz-Rico, Patricio Santillán-Doherty

{"title":"A comparative study of immunotherapy as second-line treatment and beyond in patients with advanced non-small-cell lung carcinoma.","authors":"Jerónimo Rafael Rodríguez-Cid, Sonia Carrasco-Cara Chards, Iván Romarico González-Espinoza, Vanessa García-Montes, Julio César Garibay-Díaz, Osvaldo Hernández-Flores, Rodrigo Riera-Sala, Anna Gozalishvili-Boncheva, Jorge Arturo Alatorre-Alexander, Luis Manuel Martínez-Barrera, Carla Paola Sánchez-Ríos, Adriana Martinez-Camacho, José Fabián Martínez-Herrera, Jordi Guzmán-Casta, Rodrigo Rafael Flores-Mariñelarena, Julián Diaz-Rico, Patricio Santillán-Doherty","doi":"10.2217/lmt-2020-0027","DOIUrl":null,"url":null,"abstract":"Background: Immunotherapy has demonstrated an improved overall survival (OS) and progression-free survival (PFS) as second-line treatment and subsequent lines compared with chemotherapy.Materials & methods: This was a retrospective review among eight medical centers comprising 100 patients with a confirmed diagnosis of non-small-cell lung carcinoma, in their second-line treatment or beyond with immune checkpoints inhibitors treatment. The current study aimed to analyze effectiveness of immunotherapy in second-line treatment or further in the Mexican population, using PFS rate, OS rate and the best objective response to treatment by RECIST 1.1 as a surrogate of effectiveness.Results: In total, 100 patients met the criteria for enrollment in the current study. From the total study population, 49 patients (49.0%) were male and 51 (51.0%) were female, with an average age of 60 years and stage IV as the most prevalent clinical stage at the beginning of the study. A total of 61 patients (61.0%) had partial response; 11 (11.0%) stable disease; 2 (2.0%), complete response, 4 (4.0%), progression; and 22 (22.0%) were nonevaluable. We found a median PFS of 4 months (95% CI: 3.2-4.7 months) and an OS of 9 months (95% CI: 7.2-10.7 months).Conclusion: The response to immunotherapy is similar, with an improvement in OS and PFS, independent of which drug is used. Patients using nivolumab had a better survival, although that was not statistically significant.","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2c/6a/lmt-10-47.PMC8369526.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/lmt-2020-0027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/9/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Immunotherapy has demonstrated an improved overall survival (OS) and progression-free survival (PFS) as second-line treatment and subsequent lines compared with chemotherapy.

Materials & methods: This was a retrospective review among eight medical centers comprising 100 patients with a confirmed diagnosis of non-small-cell lung carcinoma, in their second-line treatment or beyond with immune checkpoints inhibitors treatment. The current study aimed to analyze effectiveness of immunotherapy in second-line treatment or further in the Mexican population, using PFS rate, OS rate and the best objective response to treatment by RECIST 1.1 as a surrogate of effectiveness.

Results: In total, 100 patients met the criteria for enrollment in the current study. From the total study population, 49 patients (49.0%) were male and 51 (51.0%) were female, with an average age of 60 years and stage IV as the most prevalent clinical stage at the beginning of the study. A total of 61 patients (61.0%) had partial response; 11 (11.0%) stable disease; 2 (2.0%), complete response, 4 (4.0%), progression; and 22 (22.0%) were nonevaluable. We found a median PFS of 4 months (95% CI: 3.2-4.7 months) and an OS of 9 months (95% CI: 7.2-10.7 months).

Conclusion: The response to immunotherapy is similar, with an improvement in OS and PFS, independent of which drug is used. Patients using nivolumab had a better survival, although that was not statistically significant.

Abstract Image

查看原文

晚期非小细胞肺癌患者二线治疗及以后免疫疗法的比较研究。

背景：与化疗相比，免疫疗法在二线治疗及后续治疗中改善了总生存期（OS）和无进展生存期（PFS）：这是一项在8个医疗中心进行的回顾性研究，共有100名确诊为非小细胞肺癌的患者接受了免疫检查点抑制剂的二线治疗或后续治疗。本研究旨在分析免疫疗法在墨西哥人群中二线治疗或进一步治疗的有效性，使用 PFS 率、OS 率和 RECIST 1.1 最佳客观治疗反应作为有效性的替代指标：共有 100 名患者符合本次研究的入组标准。在所有研究人群中，49 名患者（49.0%）为男性，51 名患者（51.0%）为女性，平均年龄为 60 岁，研究开始时最常见的临床分期为 IV 期。共有 61 名患者（61.0%）有部分反应；11 名（11.0%）病情稳定；2 名（2.0%）完全反应，4 名（4.0%）病情进展；22 名（22.0%）无价值。我们发现中位 PFS 为 4 个月（95% CI：3.2-4.7 个月），OS 为 9 个月（95% CI：7.2-10.7 个月）：结论：对免疫疗法的反应相似，OS和PFS均有改善，与使用哪种药物无关。使用 nivolumab 的患者生存率更高，尽管这在统计学上并不显著。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文